Annual Total Liabilities
$413.82 M
+$223.55 M+117.50%
December 31, 2024
Summary
- As of March 13, 2025, RXRX annual total liabilities is $413.82 million, with the most recent change of +$223.55 million (+117.50%) on December 31, 2024.
- During the last 3 years, RXRX annual total liabilities has risen by +$346.41 million (+513.91%).
- RXRX annual total liabilities is now -18.04% below its all-time high of $504.87 million, reached on December 31, 2020.
Performance
RXRX Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$413.82 M
+$211.88 M+104.92%
December 31, 2024
Summary
- As of March 13, 2025, RXRX quarterly total liabilities is $413.82 million, with the most recent change of +$211.88 million (+104.92%) on December 31, 2024.
- Over the past year, RXRX quarterly total liabilities has increased by +$211.88 million (+104.92%).
- RXRX quarterly total liabilities is now -18.05% below its all-time high of $504.97 million, reached on March 31, 2021.
Performance
RXRX Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
RXRX Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +117.5% | +104.9% |
| 3 y3 years | +513.9% | +104.9% |
| 5 y5 years | +83.3% | +104.9% |
RXRX Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +513.9% | at high | +513.9% |
| 5 y | 5-year | -18.0% | +513.9% | -18.1% | +640.6% |
| alltime | all time | -18.0% | +513.9% | -18.1% | +640.6% |
Recursion Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $413.82 M(+117.5%) | $413.82 M(+104.9%) |
| Sep 2024 | - | $201.94 M(+5.5%) |
| Jun 2024 | - | $191.41 M(+22.2%) |
| Mar 2024 | - | $156.70 M(-17.6%) |
| Dec 2023 | $190.26 M(-11.7%) | $190.26 M(-1.3%) |
| Sep 2023 | - | $192.86 M(-2.5%) |
| Jun 2023 | - | $197.74 M(+0.3%) |
| Mar 2023 | - | $197.19 M(-8.5%) |
| Dec 2022 | $215.48 M | $215.48 M(-3.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $223.50 M(-4.9%) |
| Jun 2022 | - | $234.94 M(-2.4%) |
| Mar 2022 | - | $240.75 M(+257.2%) |
| Dec 2021 | $67.41 M(-86.6%) | $67.41 M(+13.1%) |
| Sep 2021 | - | $59.57 M(+6.6%) |
| Jun 2021 | - | $55.88 M(-88.9%) |
| Mar 2021 | - | $504.97 M(+0.0%) |
| Dec 2020 | $504.87 M(+123.7%) | - |
| Dec 2020 | - | $504.87 M |
| Dec 2019 | $225.70 M | - |
FAQ
- What is Recursion Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals annual total liabilities year-on-year change?
- What is Recursion Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Recursion Pharmaceuticals?
- What is Recursion Pharmaceuticals quarterly total liabilities year-on-year change?
What is Recursion Pharmaceuticals annual total liabilities?
The current annual total liabilities of RXRX is $413.82 M
What is the all time high annual total liabilities for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high annual total liabilities is $504.87 M
What is Recursion Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, RXRX annual total liabilities has changed by +$223.55 M (+117.50%)
What is Recursion Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of RXRX is $413.82 M
What is the all time high quarterly total liabilities for Recursion Pharmaceuticals?
Recursion Pharmaceuticals all-time high quarterly total liabilities is $504.97 M
What is Recursion Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, RXRX quarterly total liabilities has changed by +$211.88 M (+104.92%)